FDA approval of Varipulse Platform to treat refractory paroxysmal atrial fibrillation (AFib)

The Varipulse Platform is designed to enable AFib treatment with a single device that combines PFA therapy and advanced mapping with the CARTO 3 System, the world’s leading 3D electro-anatomical cardiac mapping system.

 Strategically developed for full integration with CARTO, the Varipulse Platform enables: i.  The accuracy and safety of ablation procedures through precise energy delivery and real-time visualization of catheter positioning.^{.. ii.} Minimal- to zero-fluoro workflow through seamless integration with the intracardiac echocardiography (ICE) ultrasound portfolio providing real-time imaging. iii Confidence in treatment delivered through tissue proximity indication and lesion tagging, providing electrophysiologists with feedback that has proven to be critical for lesion durability and long-term outcomes. iii. A single transseptal zero exchange workflow for an efficient and predictable procedure. iv. A comprehensive solution to seamlessly address both routine and complex AFib ablations.

“We have learned that with PFA technology, mapping integration is critically important for electrophysiologists to ‘see’ inside the heart and deliver pulsed field energy with accuracy,” explained Luigi Di Biase, MD, PhD, FACC, FHRS, System Director Electrophysiology at Montefiore Health System, Professor of Medicine (Cardiology) Albert Einstein College of Medicine at Montefiore Hospital. With this  approval, electrophysiologists will have the ability to use an integrated mapping system – CARTO – for PFA procedures, enabling a singular, versatile workflow, that could reduce procedure time, potentially driving positive results for patients.”

The approval is supported by data from the admIRE study, a prospective, multi-center, non-randomized trial. Twelve-month outcome data from the pivotal phase of the admIRE study were published in Circulation ( previously cited). Among 291 patients across 30 healthcare centers in the U.S., 100% achieved acute procedural success, including 98% with first-pass isolation recorded per vein. 85% achieved peak primary effectiveness when 73-96 applications were applied per vein (n=85), showed minimal adverse events (2.9%), and 25% of procedures were performed without fluoroscopy, likely attributable to integration with the CARTO 3 System.

“With this approval, we are excited to bring the Varipulse Platform to electrophysiologists and patients in the U.S., where AFib impacts nearly eight million people,” said Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech. “As the only PFA platform uniquely designed for seamless integration with the CARTO 3 System, we are confident that this eagerly awaited platform will be a valuable tool for physicians in performing safe, effective and efficient AFib procedures with an intuitive and reproducible workflow, and minimal-to-no fluoroscopy.”

AFib is the most common type of cardiac arrhythmia and affects more than 8 million people in the United States and more than 50 million people worldwide. Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. Despite these projections, about one-third of patients with AFib are not aware they have the condition, and AFib often goes unrecognized until the onset of complications. Catheter ablation is a safe and effective procedure when drugs don’t work to help restore the heart’s incorrect electrical signals, which cause an abnormal heart rhythm.

“With a growing prevalence of atrial fibrillation around the world, innovative solutions are critical in expanding options for patients and helping electrophysiologists treat AFib effectively and efficiently,” said Andrea Natale, M.D., Executive Medical Director, Texas Cardiac Arrythmia Institute, St. David’s Medical Center. “The Varipulse Platform enables efficient procedures with a favorable safety profile, allowing me to treat more patients and get them back to their normal lives.”

In addition to the Varipulse Platform, Johnson & Johnson MedTech is committed to developing a comprehensive suite of PFA technologies, including the investigational Dual Energy Thermocool Smartouch .SF Catheter – which is being studied to deliver both radiofrequency and PF energy, and the Omnipulse Catheter – a large-tip, 12 mm focal catheter with contact force sensing and a Trueref reference electrode.  The Dual Energy Thermocool Smartouch, SF Catheter and the Omnipulse Catheter are investigational and not available for sale or distribution in any market.